October 28, 2020

UOW congratulates Australian Technology Company of the Year Electrogenics

Award recognises UOW developed MOSkin medical radiation detection technology

The University of Wollongong (UOW) congratulates med-tech company Electrogenics on being named Australian Technology Company of the Year in the Australian Technology Competition 2020.

As well as winning the grand prize, Electrogenics won the Medtech and Pharma Award. The Australian Technologies Competition seeks to identify and accelerate Australian technology scaleups with the greatest global potential. It is supported by the Department of Industry, Science, Energy and Resources, the Industry Growth Centres and industry partners.

Electrogenics is commercialising MOSkin, the world’s most advanced and cost-effective medical radiation sensor technology, which was developed at UOW.

The award is an important recognition for MOSkin as it proceeds along on the pathway to commercialisation. UOW has granted Electrogenics the exclusive global license and commercialisation rights for MOSkin.

A pre-IPO offering is underway seeking up to $4 million and Electrogenics has plans to list on the Australian Stock Exchange in around 12 months.

MOSkin precisely measures radiation skin doses and actual dose rates in real time in tissue and organs. Researchers at UOW’s world leading Centre for Medical Radiation Physics (CMRP), led by Distinguished Professor Anatoly Rozenfeld, developed the MOSkin technology.

“MOSkin radiation sensor technology provides peace of mind for the patient and physician,” Professor Rozenfeld said.

“It is the only real-time radiation sensor that provides an accurate measure of dose to the skin during radiation therapy treatment or diagnostic radiology procedures.

“Congratulations to Electrogenics on winning this important award, which shows that the commercialisation of this technology is on the right track.

“It has been a long journey, more than a decade, to get to where we are now. The goal has always been improved treatment for people with cancer, to help people to live longer and enjoy life even with cancer.”

Electrogenics Chairman Kim Lyle said, “The Electrogenics Laboratories directors and shareholders, our research and development partner UOW, our commercialisation partners and our Australian and ASEAN distributors are all tremendously proud and excited to be a part of the global rollout of the ground breaking MOSkin medical radiation sensors.

“Being recognised as the Australian Technology Company of the Year 2020 further underscores the importance of this life-saving technology.”

MOSkin’s design allows greater real time control of the amount of radiation delivered, leading to better outcomes for patients by reducing the incidence of under or over delivery of radiation. It is the only sensor today that meets the International Commission on Radiation Measurements and Units standard for skin dosimetry.

By providing a highly accurate and reliable real-time measurement of medical radiation dose, MOSkin allows clinicians to be confident that they are targeting the cancer more effectively while minimising damage to surrounding healthy tissue.

The St George Hospital Cancer Care Centre now uses MOSkin routinely for in vivo real-time dose monitoring for prostate cancer patients treated with brachytherapy, allowing accelerated treatment.

The MOSkin project is an exemplar of successful industry engagement by UOW researchers and of the community impact that UOW research can deliver.